Cardiff Oncology, Inc. Common Stock (CRDF) Stock Price

CRDFStock

$1.02−56.98%52W

Market Cap$79.35M

P/E—

PEG Ratio—

Div yield—

Beta1.41

CRDF Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-47.27%

Price vs S&P 500 (4W)18.95%

VGM Score30.35

Book Value / Share (Quarterly)$0.51

P/TBV (Annual)0.50x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.99%

Cash Flow / Share (Quarterly)$-0.55

Price vs S&P 500 (YTD)-76.44%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-8526.10%

EPS (TTM)$-0.67

10-Day Avg Trading Volume0.78M

EPS Excl Extra (TTM)$-0.67

Revenue Growth (5Y)9.89%

EPS (Annual)$-0.69

ROI (Annual)-101.02%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-8131.43%

Cash / Share (Quarterly)$0.67

Revenue Growth QoQ (YoY)-62.39%

ROA (Last FY)-74.09%

Revenue Growth TTM (YoY)-10.71%

EBITD / Share (TTM)$-0.70

ROE (5Y Avg)-54.35%

Operating Margin (TTM)-9033.90%

Cash Flow / Share (Annual)$-0.56

P/B Ratio2.28x

P/B Ratio (Quarterly)3.19x

Net Income / Employee (Annual)$-1,479,100

EV / Revenue (TTM)134.72x

Net Interest Coverage (TTM)-100.63x

ROA (TTM)-71.45%

EPS Incl Extra (Annual)$-0.69

Current Ratio (Annual)3.67x

Quick Ratio (Quarterly)3.20x

3-Month Avg Trading Volume1.29M

52-Week Price Return-56.98%

Revenue / Employee (TTM)$16,900

Tangible BV / Share (Quarterly)$1.74

P/S Ratio (Annual)133.68x

Asset Turnover (Annual)0.01x

52-Week High$3.31

Operating Margin (5Y Avg)-8586.53%

EPS Excl Extra (Annual)$-0.69

CapEx CAGR (5Y)-26.84%

Tangible BV CAGR (5Y)74.85%

26-Week Price Return-36.03%

Quick Ratio (Annual)3.59x

13-Week Price Return-44.25%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.27x

Enterprise Value$70.73M

Revenue / Share Growth (5Y)-12.85%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-28.19%

Revenue / Employee (Annual)$19,100

Pretax Margin (Annual)-7732.04%

Cash / Share (Annual)$0.85

3-Month Return Std Dev105.45%

Gross Margin (5Y Avg)-134.65%

Net Income / Employee (TTM)$-1,443,900

ROE (Last FY)-101.02%

Net Interest Coverage (Annual)-65.17x

EPS Basic Excl Extra (Annual)$-0.69

Receivables Turnover (TTM)1.76x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.67

Receivables Turnover (Annual)0.72x

ROI (TTM)-95.50%

P/S Ratio (TTM)151.00x

Pretax Margin (5Y Avg)-8131.43%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$2.38

Price vs S&P 500 (52W)-75.29%

Year-to-Date Return-64.48%

5-Day Price Return12.63%

EPS Normalized (Annual)$-0.69

ROA (5Y Avg)-44.76%

Net Profit Margin (Annual)-7732.04%

Month-to-Date Return16.67%

Cash Flow / Share (TTM)$-0.91

EBITD / Share (Annual)$-0.73

Operating Margin (Annual)-8256.32%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-54.35%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-0.67

P/TBV (Quarterly)0.68x

P/B Ratio (Annual)4.17x

Pretax Margin (TTM)-8526.10%

Book Value / Share (Annual)$0.66

Price vs S&P 500 (13W)-47.04%

Beta1.41x

Revenue / Share (TTM)$0.01

ROE (TTM)-95.50%

52-Week Low$0.76

vGradeD

gGradeD

mGradeD

vgmGradeD

CRDF Earnings Surprise History

Q2 25-0.21est. -0.20

Q3 25-0.17est. -0.20

Q4 25-0.11est. -0.20

Q1 26-0.18est. -0.12

Q2 26-0.14est. -0.16

CRDF Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.07

3.86

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRDFCardiff Oncology, Inc. Common Stock	D	D	D	$1.02
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Cardiff Oncology, Inc. Common Stock

Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor designed to enhance standard cancer treatments through combination therapy. The company is advancing clinical trials in RAS-mutated metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, triple negative breast cancer, and chronic myelomonocytic leukemia.